Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproate + R-CHOP in DLBCL
NCT01622439Phase 2Completed
- Sponsor
- Skåne University Hospital
- Start
- Jun 2012
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valproic acid in diffuse large B-cell lymphoma (DLBCL), sponsored by Skåne University Hospital. Primary endpoint: Maximum Tolerable Dose at 18 weeks. Started Jun 2012; status: completed.
02
Drugs
valproic acid
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01622439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01622439.